Pzena Investment Management LLC Purchases New Position in Humana Inc. $HUM

Pzena Investment Management LLC acquired a new position in Humana Inc. (NYSE:HUM – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,403,136 shares of the insurance provider’s stock, valued at approximately $1,749,014,000. Humana comprises approximately 5.1% of Pzena Investment Management LLC’s holdings, making the stock its 2nd largest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HUM. Citizens Financial Group Inc. RI acquired a new stake in Humana in the second quarter valued at approximately $739,000. Pavion Blue Capital LLC bought a new stake in Humana in the second quarter worth approximately $218,000. MidFirst Bank acquired a new position in shares of Humana during the 2nd quarter worth $35,000. BlackRock Inc. acquired a new position in shares of Humana during the 2nd quarter worth $4,138,160,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Humana during the 2nd quarter valued at $238,000. Institutional investors own 92.38% of the company’s stock.

Get Humana alerts:

Humana Trading Down 1.5%

Shares of Humana stock opened at $383.18 on Tuesday. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88. The company’s fifty day simple moving average is $382.57 and its 200-day simple moving average is $277.00. The company has a market cap of $46.01 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 2.23 and a beta of 0.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM – Get Free Report) last released its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analysts’ expectations of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.27 EPS. As a group, sell-side analysts expect that Humana Inc. will post 9.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HUM shares. Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 price objective for the company in a research note on Wednesday, July 29th. Sanford C. Bernstein reissued an “outperform” rating and set a $425.00 target price on shares of Humana in a research report on Wednesday, June 3rd. Barclays boosted their price target on Humana from $344.00 to $407.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. UBS Group began coverage on Humana in a research note on Thursday, July 30th. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. increased their price objective on Humana from $316.00 to $393.00 and gave the company a “neutral” rating in a report on Monday, August 10th. Fourteen research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $395.22.

View Our Latest Research Report on HUM

About Humana

(Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Further Reading

• Five stocks we like better than Humana
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.